Eli Lilly's (LLY) Alzheimer's drug will be reassessed by the National Institute for Health and Care Excellence after a successful appeal against a prior decision blocking its use in the state-run National Health Service, Bloomberg reported Friday.

The regulator will review earlier guidance that found the benefits of donanemab, marketed as Kisunla, did not justify its cost for public use, the report said.

The drug is approved in the UK but is current available only through private healthcare.

Lilly told Bloomberg the reassessment will consider factors including unpaid caregiver costs, long-term data and infusion cost estimates.

The company did not immediately respond to MT Newswires request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)